ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1662

Unrecognised, Subclinical, Structural or Functional Lung Changes in Rheumatoid Arthritis Is Associated with a Higher Risk of Developing Serious Respiratory Tract Infection
Abstract Number: 1663

The Influence of Comorbidity on Mortality in Patients with Rheumatoid Arthritis 1980-2015: A Longitudinal Population-based Study in Western Australia
Abstract Number: 1664

Changes in Physical Function Were Not Associated with Clinically Important Changes in Muscle Strength or Physical Performance over Time – A Cohort Study
Abstract Number: 1665

Physical Activity Moderates Inflammatory Gene Expression in Rheumatoid Arthritis
Abstract Number: 1666

Association of Objectively Measured Sleep Characteristics with Rheumatoid Arthritis Disease Activity
Abstract Number: 1667

Efficacy of Plasma Phosphoethanolamine as a Biomarker for Rheumatoid Arthritis-associated Depression
Abstract Number: 1668

Unmet Need in Early Rheumatoid Arthritis – Why Do Some Patients Do Badly Despite Modern Treat-to-target Strategies of Care? Results from the Scottish Early RA (SERA) Inception Cohort
Abstract Number: 1669

Minimal Erosive Volume Needed for Radiographic Identification of Erosions in the Metacarpophalangeal Joints in Rheumatoid Arthritis. a Comparative Analysis of High Resolution Peripheral Quantitative Computed Tomography and Conventional Radiography
Abstract Number: 1670

Increased Prevalence of Gastroesophageal Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Abstract Number: 1671

COVID-19 in Patients with Rheumatoid Arthritis Compared to Patients with Osteoarthritis During the Pandemic in New York City
Abstract Number: 1672

Many Better, Many Worse: Mean PROMIS-29 Scores Mask Significant Shifts During COVID-19 in RA
Abstract Number: 1673

Riding Multiple Waves of Uncertainty: Real World Canadian RA Patient Outcomes over 1 Year of COVID-19 Restrictions
Abstract Number: 1674

Effectiveness and Safety of Tofacitinib in Canadian Patients with RA: Primary Results from a Multicenter, Observational Study
Abstract Number: 1675

Risk of Malignancy in Patients Treated with Tofacitinib: Results from the Safety of TofAcitinib in Routine Care Patients with Rheumatoid Arthritis (STAR-RA) Study
Abstract Number: 1676

Safety of Baricitinib in Japanese Patients with Rheumatoid Arthritis (RA): The 2020 Interim Report from All-case Post Marketing Surveillance in Clinical Practice

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].